James Khatcheressian

5.6k total citations · 2 hit papers
24 papers, 2.8k citations indexed

About

James Khatcheressian is a scholar working on Oncology, Cancer Research and Public Health, Environmental and Occupational Health. According to data from OpenAlex, James Khatcheressian has authored 24 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Cancer Research and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in James Khatcheressian's work include Breast Cancer Treatment Studies (7 papers), Palliative Care and End-of-Life Issues (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). James Khatcheressian is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Palliative Care and End-of-Life Issues (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). James Khatcheressian collaborates with scholars based in United States, Canada and India. James Khatcheressian's co-authors include Thomas J. Smith, Hyman B. Muss, Mark R. Somerfield, Nancy E. Davidson, Antonio C. Wolff, Victor G. Vogel, F. Halberg, Eva Grunfeld, Jeffrey Crawford and Kari Bohlke and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

James Khatcheressian

22 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

2015 589 citations Thomas J. Smith, Kari Bohlke et al. Journal of Clinical Oncology profile →
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

2016 446 citations Hope S. Rugo, R. Bryan Rumble et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Khatcheressian United States	14	1.9k	858	743	500	326	24	2.8k
Johanneke E.A. Portielje Netherlands	33	1.7k 0.9×	745 0.9×	571 0.8×	193 0.4×	249 0.8×	144	3.4k
Mariano Santaquilani Italy	13	1.7k 0.9×	403 0.5×	770 1.0×	192 0.4×	192 0.6×	19	3.1k
Athanasios Pallis Greece	31	1.5k 0.8×	369 0.4×	1.1k 1.5×	222 0.4×	197 0.6×	103	2.7k
H. Anderson Sweden	28	1.4k 0.8×	582 0.7×	603 0.8×	482 1.0×	303 0.9×	51	2.8k
Marc Colonna France	29	1.5k 0.8×	340 0.4×	427 0.6×	285 0.6×	157 0.5×	122	2.7k
M. Nooij Netherlands	29	1.4k 0.7×	778 0.9×	1.3k 1.7×	612 1.2×	111 0.3×	45	2.9k
T Bates United Kingdom	29	1.3k 0.7×	1.1k 1.3×	735 1.0×	461 0.9×	193 0.6×	111	2.7k
Andrea Veronesi Italy	28	1.6k 0.9×	630 0.7×	676 0.9×	256 0.5×	124 0.4×	135	2.8k
Gerardo Colón‐Otero United States	30	2.0k 1.1×	528 0.6×	608 0.8×	170 0.3×	199 0.6×	99	3.5k
Jacques Fracheboud Netherlands	33	2.3k 1.2×	866 1.0×	492 0.7×	230 0.5×	103 0.3×	66	2.9k

Countries citing papers authored by James Khatcheressian

Since Specialization

Citations

This map shows the geographic impact of James Khatcheressian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Khatcheressian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Khatcheressian more than expected).

Fields of papers citing papers by James Khatcheressian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Khatcheressian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Khatcheressian. The network helps show where James Khatcheressian may publish in the future.

Co-authorship network of co-authors of James Khatcheressian

This figure shows the co-authorship network connecting the top 25 collaborators of James Khatcheressian. A scholar is included among the top collaborators of James Khatcheressian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Khatcheressian. James Khatcheressian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Stephen D., Javier Muñoz, Don A. Stevens, et al.. (2019). Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab. Blood. 134(Supplement_1). 3981–3981. 6 indexed citations

Hamlin, Paul A., Bruce D. Cheson, Charles M. Farber, et al.. (2018). The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 36(15_suppl). 7511–7511. 6 indexed citations

Vahdat, Linda T., Rachel M. Layman, Denise A. Yardley, et al.. (2017). Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. The Oncologist. 22(3). 245–254. 21 indexed citations

Hamlin, Paul A., Charles M. Farber, Timothy S. Fenske, et al.. (2017). THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES. Hematological Oncology. 35(S2). 74–74. 3 indexed citations

Rugo, Hope S., R. Bryan Rumble, Erin Macrae, et al.. (2016). Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology. 34(25). 3069–3103. 446 indexed citations breakdown →

Himelstein, Andrew L., Rui Qin, Paul J. Novotny, et al.. (2015). CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.. Journal of Clinical Oncology. 33(15_suppl). 9501–9501. 14 indexed citations

Smith, Thomas J., Kari Bohlke, Gary H. Lyman, et al.. (2015). Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 33(28). 3199–3212. 589 indexed citations breakdown →

Hainsworth, John D., et al.. (2013). Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial. Clinical Genitourinary Cancer. 11(3). 270–275. 31 indexed citations

Khatcheressian, James, Patricia A. Hurley, Elissa Bantug, et al.. (2012). Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 31(7). 961–965. 431 indexed citations

10.

Schuchter, Lynn M., Lawrence E. Flaherty, Omid Hamid, et al.. (2012). A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.. Journal of Clinical Oncology. 30(15_suppl). 8567–8567. 1 indexed citations

11.

Smith, Thomas J., et al.. (2011). A Pilot Trial of Decision Aids to Give Truthful Prognostic and Treatment Information to Chemotherapy Patients with Advanced Cancer. PubMed. 9(2). 79–86. 83 indexed citations

12.

Griggs, Jennifer J., Mark R. Somerfield, Holly Anderson, et al.. (2011). American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer. Journal of Clinical Oncology. 29(29). 3939–3942. 40 indexed citations

13.

Dow, Lindsay, et al.. (2010). Pilot trial of decision aids for patients with advanced breast, lung, colorectal, or prostate cancer.. Journal of Clinical Oncology. 28(15_suppl). 9108–9108. 1 indexed citations

14.

Smith, Thomas J., et al.. (2010). Giving honest information to patients with advanced cancer maintains hope.. PubMed. 24(6). 521–5. 115 indexed citations

15.

Hackney, Mary Helen, et al.. (2008). Ovarian Suppression in the Management of Premenopausal Breast Cancer: Methods and Efficacy in Adjuvant and Metastatic Settings. Oncology. 75(3-4). 192–202. 6 indexed citations

16.

Khatcheressian, James, et al.. (2008). Breast cancer follow-up in the adjuvant setting. Current Oncology Reports. 10(1). 38–46. 13 indexed citations

17.

Khatcheressian, James & Thomas J. Smith. (2007). Review: Adding cytotoxic drugs to a chemotherapy regimen increases tumor response rates and toxicity, but not survival in metastatic breast cancer. ACP Journal Club. 146(1). 5–5. 2 indexed citations

18.

Khatcheressian, James, et al.. (2005). Improving palliative and supportive care in cancer patients.. PubMed. 19(10). 1365–76; discussion 1377. 18 indexed citations

19.

Smith, Thomas J. & James Khatcheressian. (2005). Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.. 321 indexed citations

20.

Smith, Thomas J. & James Khatcheressian. (2005). Review: Chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer. ACP Journal Club. 143(3). 58–58. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact